• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PHENYTOIN Drug Record

  • Summary
  • Interactions
  • Claims
  • PHENYTOIN chembl:CHEMBL16 Approved

    Alternate Names:

    DILABID
    PHENYTEK
    DILANTIN-125
    HYDANTOL
    NSC-8722
    DIPHENYLHYDANTOIN
    PHENYTEX
    PHENYTOIN
    SM-88 COMPONENT PHENYTOIN
    PHENTYTOIN
    DILANTIN-30
    DILANTIN
    PHENYTEX®
    5,5-DIPHENYL-IMIDAZOLIDINE-2,4-DIONE
    PHENYTOIN SODIUM
    5,5-DIPHENYLTETRAHYDRO-1H-2,4-IMIDAZOLEDIONE
    5,5-DIPHENYLIMIDAZOLIDINE-2,4-DIONE
    DILANTIN®
    FENITOINA
    PHENYTOINE
    EPANUTIN®
    PHENYTOINUM
    pubchem.compound:1775
    drugbank:00252
    chemidplus:57-41-0
    rxcui:8183
    chembl:CHEMBL16

    Drug Info:

    FDA Approval Approved before 1982
    Drug Class small molecule
    Drug Indications Anticonvulsants
    Drug Class anticonvulsants
    Year of Approval approved before 1982
    (5 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Musselman et al., Preliminary evidence of phenytoin-induced alterations in embryonic gene expression in a mouse model., Reprod. Toxicol.
    Tate et al., 2006, A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose., Pharmacogenet. Genomics
    Mantegazza et al., 2010, Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders., Lancet Neurol
    Tate et al., 2005, Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin., Proc. Natl. Acad. Sci. U.S.A.
    Ericsson et al., Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid., Epilepsia
    Gryn SE et al., 2014, Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort., Pharmacogenet Genomics
    Mazaleuskaya LL et al., 2015, PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses., Pharmacogenet Genomics
    Fleckman et al., 1981, Effect of trifluoperazine, D600, and phenytoin on depolarization- and thyrotropin-releasing hormone-induced thyrotropin release from rat pituitary tissue., Endocrinology
    Azzato EM et al., 2010, Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations., Pharmacogenet Genomics
    Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
    Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
    Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
    Ohnishi et al., 1997, Direct inhibitions of the activities of steroidogenic cytochrome P-450 mono-oxygenase systems by anticonvulsants., J. Steroid Biochem. Mol. Biol.
    Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
    Dean et al., 1999, Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene., Clin. Genet.
    Mitiushin et al., 1978, [Several types of mitochondrial ultrastructure in animal cell mitochondria and their relationship to energy production]., Tsitologiia
    Swadron et al., 2004, A comparison of phenytoin-loading techniques in the emergency department., Acad Emerg Med
    Yang M et al., 2012, Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer., Breast Cancer Res Treat
    Wong et al., 2005, The effects of phenytoin and its metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin on cellular glucose transport., Life Sci.
    Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
    Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
    Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
    Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
    Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
    Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
    Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
    Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
    Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
    Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
    Kobayashi K et al., 2004, Key structural features of ligands for activation of human pregnane X receptor., Drug Metab Dispos
    Turan et al., 2004, Do vascular endothelial growth factor and basic fibroblast growth factor promote phenytoin's wound healing effect in rat? An immunohistochemical and histopathologic study., Dermatol Surg
    Lucas PT et al., 2005, An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin., Epilepsy Res
    Keppel Hesselink JM, 2017, Phenytoin: a step by step insight into its multiple mechanisms of action-80 years of mechanistic studies in neuropharmacology., J Neurol
    Calandre et al., The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients., Epilepsia
    Tutor-Crespo et al., [A study of some indirect biochemical markers in the evaluation of enzymatic induction caused by antiepileptic drugs]., Rev Neurol
  • PHENYTOIN   CFHR4

    Interaction Score: 1.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PHENYTOIN   TRH

    Interaction Score: 0.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6262046


    Sources:
    NCI

  • PHENYTOIN   UGT2B15

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26049587


    Sources:
    PharmGKB

  • PHENYTOIN   CYP2A6

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11038165 8886611 19702528 19442086 14704462 12386121


    Sources:
    PharmGKB

  • PHENYTOIN   EPHX1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19952982


    Sources:
    PharmGKB

  • PHENYTOIN   AQP4

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18572411


    Sources:
    DTC

  • PHENYTOIN   POU5F1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PHENYTOIN   SLC2A1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15698863


    Sources:
    NCI

  • PHENYTOIN   GGT1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1346382 12402220


    Sources:
    NCI

  • PHENYTOIN   MTHFR

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12083967 10563481


    Sources:
    NCI PharmGKB

  • PHENYTOIN   UGT1A6

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26049587


    Sources:
    PharmGKB

  • PHENYTOIN   CYP1A1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26951882 21121773


    Sources:
    PharmGKB

  • PHENYTOIN   NTF3

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7841657


    Sources:
    NCI

  • PHENYTOIN   UGT1A9

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26049587


    Sources:
    PharmGKB

  • PHENYTOIN   SCN1A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    17001291 20298965 15805193


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • PHENYTOIN   TG

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3935423


    Sources:
    NCI

  • PHENYTOIN   SCN2A

    Interaction Score: 0.16

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    25155934 23859570 18784617 15805193


    Sources:
    ChemblInteractions PharmGKB

  • PHENYTOIN   SCN5A

    Interaction Score: 0.11

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    150666 15001403 22678159


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • PHENYTOIN   CYP19A1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9182861


    Sources:
    NCI

  • PHENYTOIN   NAT2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PHENYTOIN   VEGFA

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15458527


    Sources:
    NCI

  • PHENYTOIN   SCN3A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    15922564 15805193


    Sources:
    ChemblInteractions

  • PHENYTOIN   CYP2B6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17638512


    Sources:
    PharmGKB

  • PHENYTOIN   HLA-B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • PHENYTOIN   SCN8A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    15805193


    Sources:
    ChemblInteractions

  • PHENYTOIN   NR1I2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14977870 15039302


    Sources:
    PharmGKB

  • PHENYTOIN   GABRA1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28349209


    Sources:
    PharmGKB

  • PHENYTOIN   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12673034


    Sources:
    NCI

  • PHENYTOIN   SCN7A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Sodium channel alpha subunit blocker

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENYTOIN   SCN11A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENYTOIN   SCN4A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENYTOIN   SCN9A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENYTOIN   SCN10A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    blocker (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sodium channel alpha subunit blocker
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PHENYTOIN   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC FDA

  • PHENYTOIN   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24915025 22931300


    Sources:
    DTC PharmGKB

  • PHENYTOIN   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC FDA

  • PHENYTOIN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PHENYTOIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • PHENYTOIN   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: PHENYTOIN

    • Version: 01-August-2011

    Alternate Names:
    PHENYTOIN Primary Drug Name

    Drug Info:
    Year of Approval approved before 1982
    Drug Class anticonvulsants

    Publications:

  • TdgClinicalTrial: PHENYTOIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anticonvulsants
    Drug Class small molecule
    FDA Approval Approved before 1982

    Publications:

  • NCI: PHENYTOIN

    • Version: 14-September-2017

    Alternate Names:
    C741 NCI drug code

    Drug Info:

    Publications:
    Ericsson et al., Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid., Epilepsia
    Fleckman et al., 1981, Effect of trifluoperazine, D600, and phenytoin on depolarization- and thyrotropin-releasing hormone-induced thyrotropin release from rat pituitary tissue., Endocrinology
    Turan et al., 2004, Do vascular endothelial growth factor and basic fibroblast growth factor promote phenytoin's wound healing effect in rat? An immunohistochemical and histopathologic study., Dermatol Surg

  • DTC: PHENYTOIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL16 ChEMBL Drug ID

    Drug Info:

    Publications:
    Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: phenytoin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tate et al., 2006, A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose., Pharmacogenet. Genomics
    Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
    Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics

  • TTD: Phenytoin

    • Version: 2020.06.01

    Alternate Names:
    D0E4DW TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL16

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Phenytoin

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL16

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21